Abstract: Among patients with systemic autoimmune rheumatic diseases (SARDs), the risk of breakthrough COVID-19 infection is similar after receiving either BNT162b2 or mRNA-1273. Patients with SARDs initiating the vaccine series should be encouraged to receive whichever mRNA vaccine is available.
Introduction
Patients with systemic autoimmune rheumatic diseases (SARDs), such as rheumatoid arthritis or systemic lupus erythematosus, represent a high-risk group during the COVID-19 pandemic. Many of these patients require immunomodulatory medications—including glucocorticoids, conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), and biologics—that can potentially "blunt" the immune response to vaccination. While clinical trials established the high efficacy of mRNA vaccines in the general population, immunosuppressed individuals were largely excluded from these initial studies.
Evidence from other populations, such as veterans, suggested that the mRNA-1273 (Moderna) vaccine might offer slightly superior protection compared to BNT162b2 (Pfizer-BioNTech), possibly due to its higher mRNA dosage (100µg vs. 30µg). This study investigates whether this potential advantage persists in the SARD population, where the underlying disease and its treatment significantly impact immune function.
Methods and Study Population
Researchers conducted an observational cohort study using the Mass General Brigham (MGB) healthcare system's Enterprise Data Warehouse, which aggregates data from 14 hospitals and numerous outpatient centers in Massachusetts. To ensure accuracy, these records were linked to the Massachusetts Immunization Information System (MIIS).
The study employed a sophisticated statistical approach to address the complexities of real-world data. The researchers used time-stratified, overlap propensity score (PS) weighting to ensure the Pfizer and Moderna recipient groups were comparable across demographics, comorbidities, and specific immunomodulatory treatments. Time stratification was particularly important to account for the rapidly evolving landscape of vaccine availability and dominant viral variants.
As shown in Figure 1, the final analysis included 9,838 patients: 5,516 who received BNT162b2 and 4,322 who received mRNA-1273.
Key Results
The primary analysis found no statistically significant difference in the risk of breakthrough COVID-19 infection between the two vaccine groups. There were 446 breakthrough events in the Pfizer group and 329 in the Moderna group.
The weighted hazard ratio (HR) for breakthrough infection was 1.12 (95% CI 0.90 to 1.39) for Pfizer versus Moderna. Since the confidence interval includes 1.0, the difference does not reach statistical significance.
Sensitivity analyses focused on the pre-Omicron period (before December 15, 2021) showed a trend toward a higher risk with Pfizer (HR 1.34), but this also failed to reach statistical significance (95% CI 0.91 to 1.98). Negative control analyses, such as comparing non-COVID-related deaths, showed no difference between groups, validating the effectiveness of the propensity score weighting in removing bias.
Discussion: The "Equalizer" Effect
Several factors may explain why the slight advantage of Moderna seen in the general population was not observed here:
- Dominance of Immunosuppression: In SARD patients, the impact of immunomodulatory therapy may be a more dominant factor in determining vaccine response than the specific mRNA platform or dosage.
- Omicron as a Leveler: The emergence of the highly immune-evasive Omicron variant appeared to "wash out" any subtle differences in protection that might have existed during the Alpha or Delta waves.
- Medication Specificity: The study specifically accounted for high-impact treatments like Rituximab, a B-cell depleting therapy known to severely inhibit antibody production. By balancing these factors, the researchers ensured a fair comparison between the two vaccines.
Limitations and Conclusion
While this is a large-scale study, it may still have been underpowered to detect very small differences between the vaccines. Additionally, the data did not capture "medication holding" (patients temporarily stopping treatment around vaccination) or real-time disease activity, both of which can influence immune response.
In conclusion, for patients with SARDs on immunomodulatory medications, both mRNA vaccines provide comparable protection against breakthrough infection. The clinical takeaway is clear: patients should prioritize receiving whichever mRNA vaccine is most readily available to them. Future research should investigate the effectiveness of variant-specific boosters and "mix-and-match" strategies in this vulnerable population.
Summary updated